Cargando…

Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone

Withaferin-A (Wi-A), a secondary metabolite extracted from Ashwagandha (Withania somnifera), has been shown to possess anticancer activity. However, the molecular mechanism of its action and the signaling pathways have not yet been fully explored. We performed an inverse virtual screening to investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malik, Vidhi, Radhakrishnan, Navaneethan, Kaul, Sunil C., Wadhwa, Renu, Sundar, Durai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961606/ https://www.ncbi.nlm.nih.gov/pubmed/35204712 http://dx.doi.org/10.3390/biom12020212

Ejemplares similares

Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
por: Malik, Vidhi, et al.
Publicado: (2021)

Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl ester as ATP-competitive inhibitors of BRAF: A bioinformatics study
por: Malik, Vidhi, et al.
Publicado: (2021)

Molecular dynamics simulations and experimental studies reveal differential permeability of withaferin-A and withanone across the model cell membrane
por: Wadhwa, Renu, et al.
Publicado: (2021)

Differential Activities of the Two Closely Related Withanolides, Withaferin A and Withanone: Bioinformatics and Experimental Evidences
por: Vaishnavi, Kirti, et al.
Publicado: (2012)

2, 3-Dihydro-3β-methoxy Withaferin-A Lacks Anti-Metastasis Potency: Bioinformatics and Experimental Evidences
por: Chaudhary, Anupama, et al.
Publicado: (2019)

Ashwagandha Derived Withanone Targets TPX2-Aurora A Complex: Computational and Experimental Evidence to its Anticancer Activity
por: Grover, Abhinav, et al.
Publicado: (2012)

Phosphatidylserine Exposed Lipid Bilayer Models for Understanding Cancer Cell Selectivity of Natural Compounds: A Molecular Dynamics Simulation Study
por: Radhakrishnan, Navaneethan, et al.
Publicado: (2022)

Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences
por: Yu, Yue, et al.
Publicado: (2017)

Combination of Withaferin-A and CAPE Provides Superior Anticancer Potency: Bioinformatics and Experimental Evidence to Their Molecular Targets and Mechanism of Action
por: Sari, Anissa Nofita, et al.
Publicado: (2020)

Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
por: Widodo, Nashi, et al.
Publicado: (2010)

Ashwagandha Leaf Derived Withanone Protects Normal Human Cells Against the Toxicity of Methoxyacetic Acid, a Major Industrial Metabolite
por: Priyandoko, Didik, et al.
Publicado: (2011)

Protective Role of Ashwagandha Leaf Extract and Its Component Withanone on Scopolamine-Induced Changes in the Brain and Brain-Derived Cells
por: Konar, Arpita, et al.
Publicado: (2011)

Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53(Y220C) mutant: bioinformatics and experimental evidence
por: Radhakrishnan, Navaneethan, et al.
Publicado: (2021)

A Low Dose Combination of Withaferin A and Caffeic Acid Phenethyl Ester Possesses Anti-Metastatic Potential In Vitro: Molecular Targets and Mechanisms
por: Sari, Anissa Nofita, et al.
Publicado: (2022)

Marine Carotenoid Fucoxanthin Possesses Anti-Metastasis Activity: Molecular Evidence
por: Garg, Sukant, et al.
Publicado: (2019)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Bioinformatics and Molecular Insights to Anti-Metastasis Activity of Triethylene Glycol Derivatives
por: Malik, Vidhi, et al.
Publicado: (2020)

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
por: Huang, Zheng-Lan, et al.
Publicado: (2013)

Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
por: Putri, Jayarani F., et al.
Publicado: (2019)

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
Publicado: (1995)

Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
por: Shibata, Norihito, et al.
Publicado: (2018)

Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
por: Schmidt, Nina, et al.
Publicado: (2022)

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands
por: Shibata, Norihito, et al.
Publicado: (2017)

Expression of chronic myeloid leukemia oncogenes BCR-ABL (P210) and BCR-ABL (T315I) affect cellular and humoral innate immunity in Drosophila melanogaster
por: Abubaker, Dana, et al.
Publicado: (2022)

Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
por: Reckel, Sina, et al.
Publicado: (2017)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Comparative computational and experimental analyses of some natural small molecules to restore transcriptional activation function of p53 in cancer cells harbouring wild type and p53(Ser46) mutant
por: Shefrin, Seyad, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Identification and Characterization of Mortaparib(Plus)—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms
por: Sari, Anissa Nofita, et al.
Publicado: (2021)

Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes
por: Grover, Abhinav, et al.
Publicado: (2010)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

c-Fos and Dusp1 confer non-oncogene addiction in BCR-ABL induced leukemia
por: Kesarwani, Meenu, et al.
Publicado: (2017)

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1
por: Meidinna, Hazna Noor, et al.
Publicado: (2022)

Computational and in vitro experimental analyses of the anti-COVID-19 potential of Mortaparib and Mortaparib(Plus)
por: Kumar, Vipul, et al.
Publicado: (2021)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer
por: Malik, Vidhi, et al.
Publicado: (2021)

WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene
por: Montano, Giorgia, et al.
Publicado: (2015)

Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies
por: Liefwalker, Daniel F., et al.
Publicado: (2021)

Mutant p53(L194F) Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib(Plus), a Multimodal Small Molecule Inhibitor
por: Elwakeel, Ahmed, et al.
Publicado: (2021)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_673aobcu358eubsh7uap2s7jvj